What are the clinical features, diagnostic criteria, and treatment options for Melkersson‑Rosenthal syndrome?

Melkersson-Rosenthal Syndrome: Clinical Features, Diagnosis, and Treatment

Clinical Features

Melkersson-Rosenthal syndrome (MRS) is a rare neuro-muco-cutaneous disorder defined by a classic triad: recurrent orofacial edema, relapsing facial nerve paralysis, and fissured tongue—though the complete triad appears in only 8-45% of cases 1, 2. Monosymptomatic and oligosymptomatic presentations are actually more common than the full triad 1.

Key Clinical Characteristics:

• Age of onset: Mean age is 14.1 years, with higher prevalence in young adults 2, 3
• Orofacial edema: Painless, recurrent swelling affecting lips, tongue, or facial soft tissues; may become persistent over time 1, 4
• Facial paralysis: Recurrent episodes affecting the facial nerve, typically unilateral 2, 5
• Fissured tongue: Deep grooves on the tongue surface 1, 4
• Family history: Present in approximately 29.5% of cases, suggesting genetic factors 3, 5

Important Clinical Pitfalls:

The diagnosis is frequently missed because clinicians expect the complete triad. You must consider MRS when even two of the three cardinal features are present 1. The tongue edema may not be evident at every examination—patients may need to provide photographs of swelling episodes 1.

Diagnostic Approach

Diagnosis is primarily clinical, based on history and physical examination findings, with histopathology serving as supportive rather than mandatory evidence 1, 3.

Diagnostic Criteria:

• Minimum requirement: Two or more of the classic triad features 4
• Physical examination: Look specifically for lip/facial swelling, facial nerve function deficits, and tongue fissuring
• Patient history: Question about recurrent episodes, family history, and minor symptoms between attacks 3

Useful Ancillary Investigations:

• Histopathology: May show granulomatous inflammation (granulomatous cheilitis), but absence does not exclude diagnosis 1, 6
• High-resolution CT of temporal bone: Coronary reconstruction may reveal broadened fallopian canal (found in 38.6% of cases) 3
• Food allergen testing: Positive in 87% of tested patients, suggesting immune-mediated mechanisms 3
• CSF analysis: May show elevated protein levels 5
• Serum immunoglobulins: Occasionally elevated IgG 5

Differential Diagnosis to Exclude:

• Angioedema (allergic or hereditary)
• Sarcoidosis
• Crohn's disease with oral manifestations
• Infectious granulomatous conditions
• Lymphedema

Treatment Strategy

Most patients do not require treatment; intervention is indicated primarily for symptomatic edema or recurrent facial paralysis 1.

First-Line Treatment for Orofacial Edema:

Corticosteroids are the mainstay of therapy 2, 4, 5:

• Intralesional triamcinolone acetonide: Preferred for localized orofacial edema 4, 6
• Systemic corticosteroids: All patients in one series responded to systemic corticosteroid treatment 5
• Alternative regimen: Intralesional betamethasone combined with oral doxycycline 4, 6

The combination of intralesional triamcinolone acetonide with doxycycline has shown excellent clinical response 6.

Management of Facial Nerve Paralysis:

For patients with recurrent facial paralysis and appropriate electrophysiological indicators, prophylactic facial nerve decompression should be considered 3. In one series, 31 patients underwent subtotal facial nerve decompression with only one recurrence on the operated side 3.

Surgical Intervention:

Surgery is reserved for persistent lip edema unresponsive to medical therapy and provides excellent cosmetic results 2. This should be considered only after medical management has failed.

Conservative Management:

For mild cases or patients declining pharmacotherapy:

• Patient education about the benign, chronic nature of the condition 1
• Dietary modifications (given high rate of food allergen positivity) 3
• Regular follow-up monitoring 1

Treatment Algorithm:

1. Mild/intermittent symptoms: Observation, patient education, dietary counseling
2. Symptomatic orofacial edema: Intralesional triamcinolone acetonide ± oral doxycycline
3. Severe or refractory edema: Systemic corticosteroids
4. Recurrent facial paralysis with electrophysiological changes: Consider prophylactic facial nerve decompression
5. Persistent cosmetically disfiguring edema: Surgical reduction

Critical Caveat:

There are no standardized treatment protocols due to the rarity and clinical heterogeneity of MRS 1. However, the evidence consistently supports corticosteroids as first-line pharmacotherapy when treatment is necessary, with surgical options reserved for refractory cases.